In a business environment where digital innovation has become a key driver of competitiveness, the pharmaceutical industry is in a unique position. It is one of the most digitised and regulated sectors in the world, but also one of the most exposed to cyber risks.
In fact, 68% of pharmaceutical companies say that cyber risks are one of the main obstacles to effective digital transformation, according to a McKinsey study. This highlights a strategic challenge: digital security must be seen not only as a preventive measure, but as a structural component of business strategy.
A digital ecosystem with new attack surfaces
The pharmaceutical industry has accelerated its investment in research and development (R&D) and integrated advanced technologies such as artificial intelligence (AI) to optimise processes, from drug discovery to treatment personalisation. However, these initiatives have opened up new attack vectors.
Today, cybercriminals are not only looking for financial gain. In an industry where intellectual property, clinical data and regulatory processes are strategic assets, the goal of attacks can go beyond traditional ransomware, extending to the theft of sensitive information and digital espionage.
The consequences of attacks: a million-pound impact
Exposure to cyber threats in the pharmaceutical industry is not hypothetical. According to IBM Security, 82% of pharmaceutical companies have suffered cyber attacks in the last year, accumulating global losses of $3 billion.
These attacks not only affect IT systems, but can also paralyse critical operations, compromise the integrity of clinical trials and threaten corporate reputation. In such a highly regulated sector, the impact of a cyberattack can be devastating, both financially and strategically.
Spain: A strategic market undergoing transformation
In the European context, Spain stands out as the fourth largest pharmaceutical market in terms of turnover and the ninth largest worldwide. With more than 174 production plants, the country has established itself as a strategic hub for the manufacture and distribution of medicines. This growth has been driven by the digitisation of processes, the expansion of supply networks and the integration of new technologies.
However, this same expansion has increased the attack surface, especially in an environment where supply chains are more interconnected than ever. How can pharmaceutical companies protect their strategic assets in such an exposed environment?
Cybersecurity: From technical protection to business strategy
Cybersecurity has evolved from a technical function to a structural factor for business continuity. It is no longer enough to implement point solutions; a comprehensive approach is needed that addresses critical data protection, emerging threat identification and the creation of a security-oriented organisational culture.
In an industry where trust is a key asset, protecting the integrity of information is not just an operational issue, but a fundamental strategy for preserving competitiveness and reputation.
As the pharmaceutical industry continues to digitise, cybersecurity must become a strategic priority. From protecting clinical data to ensuring supply chain integrity, companies must take a proactive approach, not only to prevent attacks, but also to mitigate risks and ensure operational continuity.
Is your pharmaceutical company ready to innovate with confidence?
Learn about our cybersecurity solutions.